ArticleCureus2025
Reversible Splenial Lesion Syndrome Induced by Paracetamol and Lithium: A Report of Two Cases and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cytotoxic Lesion of the Corpus Callosum in a Patient with Acute-on-chronic Lithium Toxicity.Internal medicine (Tokyo, Japan) · 2026Article
- Reversible Splenial Lesion Syndrome Induced by Paracetamol and Lithium: A Report of Two Cases and Literature Review.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reversible splenial lesion syndrome (RESLES) is a rare neurological syndrome characterized by a reversible lesion in the splenium of the corpus callosum (SCC). Various etiologies, such as infection, high-altitude cerebral edema, seizures, antiepileptic drug withdrawal, and metabolic abnormalities, are involved in the development of RESLES. However, few studies have reported drug-induced cases of this disorder, especially those induced by paracetamol, which have not been previously documented. Firstly, a 50-year-old man with neuropsychiatric symptoms who was taking an overdose of paracetamol was referred to our hospital. Laboratory tests revealed elevated levels of liver enzymes and creatine kinase, with no signs of infection. The patient fully recovered after eight days of symptomatic treatment. Secondly, a 35-year-old female was taking 1750 mg/day lithium, 500 mg/day quetiapine, and 500 mg/day magnesium valproate for bipolar disorder (BD). She experienced generalized tremors, rigidity, and dysarthria, along with high fever, hypertension, tachycardia, and tachypnea. Her blood lithium level was 1.46 mmol/L, and her valproic acid (VPA) serum concentration was 27.00 mg/L. The patient fulfilled the diagnostic criteria for neuroleptic malignant syndrome (NMS). Symptoms and brain lesions completely resolved two weeks after discontinuing lithium and quetiapine. Both patients' cerebral magnetic resonance imaging (MRI) typically demonstrated a reversible lesion with transiently reduced diffusion in the SCC. RESLES is usually detected incidentally and is easily neglected. Our report suggests that RESLES should be considered in patients exhibiting neuropsychiatric symptoms, particularly those accompanied by taking medicine irregularly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.